Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mon... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrovira... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study t... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the oth... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in ... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ef... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hype... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimin... Read More
Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with c... Read More